穿透迷雾,各大药企在终端市场实际表现如何?核心品种是否有创新力?在当下的医药“寒冬”里,我们应该如何放平心态,合理看待医药行业估值和发展前景呢?
![传统 VS 新生:谁有资格叫做创新药企?](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![p01.png 传统 VS 新生:谁有资格叫做创新药企?](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![传统 VS 新生:谁有资格叫做创新药企?](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![p02.png 传统 VS 新生:谁有资格叫做创新药企?](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![中国首款自研P-CAB替戈拉生片获批 罗欣药业“创仿结合”战略迎新里程碑](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![传统 VS 新生:谁有资格叫做创新药企?](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
推荐阅读
![传统 VS 新生:谁有资格叫做创新药企?](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![传统 VS 新生:谁有资格叫做创新药企?](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
本篇文章来源于微信公众号:药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权
穿透迷雾,各大药企在终端市场实际表现如何?核心品种是否有创新力?在当下的医药“寒冬”里,我们应该如何放平心态,合理看待医药行业估值和发展前景呢?
推荐阅读
本篇文章来源于微信公众号:药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权